Alan Hartman joined Centerview Partners after 15 years with Merrill Lynch where he had been Head of Americas Mergers & Acquisitions and Global Head of Merrill Lynch’s Healthcare M&A Group. He was named one of the “Dealmakers of the Year” in 2006 and 2007 by Dealmaker Magazine.

Mr. Hartman’s transaction experience includes advising Pfizer in its $68 billion acquisition of Wyeth, Boston Scientific in its $25 billion acquisition of Guidant Corporation, the buyout group in its $33 billion acquisition of HCA, Astra Zeneca in its $15.2 billion acquisition of Medimmune, Celgene in its $2.9 billion acquisition of Pharmion, Immunex in its $16 billion sale to Amgen, Gilead in its $1.4 billion acquisition of CV Therapeutics, Province in its $1.7 billion sale to Lifepoint, Mylan in its $6.7 billion acquisition of Merck KGaA  generics, Biogen IDEC and Mylan in their respective proxy fights with Carl Icahn, Ventas in its $2 billion acquisition of Sunrise Senior Living REIT, IDEC in its $7 billion mergers of equals with Biogen, Icos in its $2.4 billion sale to Eli Lilly, Triad in its $2.4 billion acquisition of Quorum, Quest Diagnostics in its $1.6 billion acquisition of Unilab and AML, Pfizer it is $4.2 billion sale of its Adams division to Cadbury Schwepps.

Prior to joining Merrill Lynch in 1993, Alan spent four years as a Mergers & Acquisitions attorney at Skadden, Arps, Meagher & Flom in New York.

He received a B.S. in economics from the Wharton School of Finance and a J.D. from Harvard Law School.